Data on almost 28,000 patients suggests understanding gene variations could improve treatments for obesity
Scientists have discovered how genetics may help explain why weight-loss jabs work better for some people than others.
Variations in two genes involved in gut hormone pathways, which regulate appetite and digestion, may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines.
The findings, published in the journal Nature on Wednesday, could support future efforts to use genetic information when making treatment choices for obesity.
GLP1 receptor agonists, including semaglutide (known by the brand name Wegovy) and tirzepatide (marketed as Mounjaro), are medicines that mimic natural gut hormones.
